

KCNQ2/3/4/5 (phospho Thr217/246/223/251) Polyclonal Antibody

Catalog No: YP1006

Reactivity: Human; Mouse; Rat

Applications: WB;IHC;IF;ELISA

Target: KCNQ2/3/4/5

Fields: >>Cholinergic synapse

Gene Name: KCNQ2

Protein Name: Potassium voltage-gated channel subfamily KQT member 2

Human Gene Id: 3785/3786/9132/56479

Human Swiss Prot

No:

rot

O43526/O43525/P56696/Q9NR82

Mouse Gene ld: 16536/110862/60613/226922

Rat Gene Id: 170848/29682

Rat Swiss Prot No: O88943/O88944/Q9JK96

Immunogen: The antiserum was produced against synthesized peptide derived from human

Kv7.3/KCNQ3 around the phosphorylation site of Thr246. AA range:191-240

Specificity: Phospho-KCNQ2/3/4/5 (T217/246/223/251) Polyclonal Antibody detects

endogenous levels of KCNQ2/3/4/5 protein only when phosphorylated at

T217/246/223/251.

Formulation : Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source: Polyclonal, Rabbit, lgG

Dilution: WB 1:500-2000 IHC 1:100 - 1:300. ELISA: 1:20000. IF 1:50-200

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-

1/3



chromatography using epitope-specific immunogen.

Concentration: 1 mg/ml

Storage Stability: -15°C to -25°C/1 year(Do not lower than -25°C)

Molecularweight: 97kD

Background: The M channel is a slowly activating and deactivating potassium channel that

plays a critical role in the regulation of neuronal excitability. The M channel is formed by the association of the protein encoded by this gene and a related protein encoded by the KCNQ3 gene, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 1 (BFNC), also known as epilepsy, benign neonatal type 1 (EBN1). At least five transcript variants encoding five different isoforms have been found for this gene. [provided by RefSeq, Jul

2008],

Function: alternative products:Additional isoforms seem to exist, disease:Defects in

KCNQ2 are the cause of benign neonatal epilepsy type 1 (EBN1) [MIM:121200]. Benign neonatal epilepsy is characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset., disease: Defects in KCNQ2 are the cause of benign neonatal epilepsy with myokymia (EBNMK) [MIM:606437]. EBNMK is a syndrome characterized by benign neonatal

convulsions followed later in life by myokymia.,disease:Defects in KCNQ2 are the cause of myokymia isolated type 2 (MK2) [MIM:606437]. Myokymia is a condition characterized by spontaneous involuntary contraction of muscle fiber groups that

can be observed as vermiform movement of the overly

Subcellular Location:

Cell membrane; Multi-pass membrane protein.


Expression: In adult and fetal brain. Highly expressed in areas containing neuronal cell

bodies, low in spinal cord and corpus callosum. Isoform 2 is preferentially expressed in differentiated neurons. Isoform 6 is prominent in fetal brain,


undifferentiated neuroblastoma cells and brain tumors.

Products Images

2/3



Enzyme-Linked Immunosorbent Assay (Phospho-ELISA) for Immunogen Phosphopeptide (Phospho-left) and Non-Phosphopeptide (Phospho-right), using Kv7.3/KCNQ3 (Phospho-Thr246) Antibody



Immunohistochemistry analysis of paraffin-embedded human brain, using Kv7.3/KCNQ3 (Phospho-Thr246) Antibody. The picture on the right is blocked with the phospho peptide.